Carlyle's Claris Sells $194M Stake, Forms Injections JV

Law360, New York (December 7, 2012, 1:54 PM EST) -- Carlyle Group LP-backed Claris Lifesciences Ltd. will sell 80 percent of its emerging-markets infusions business to a pair of Japanese companies for $194 million, forming a three-way joint venture to ramp up new product innovation and output, Claris said Friday.

The Indian company will join with Otsuka Pharmaceutical Factory Inc. and Mitsui & Co. Ltd. in the deal, with Otsuka grabbing a 60 percent stake and Mitsui and Claris each claiming a 20 percent interest in the specialty generic injectables-focused business.

Otsuka and Mitsui did not...
To view the full article, register now.